Compare GIII & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIII | MNKD |
|---|---|---|
| Founded | 1956 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2006 | 2004 |
| Metric | GIII | MNKD |
|---|---|---|
| Price | $27.13 | $3.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $34.75 | $7.97 |
| AVG Volume (30 Days) | 718.6K | ★ 4.5M |
| Earning Date | 09-02-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $2,957,012,000.00 | $348,966,000.00 |
| Revenue This Year | N/A | $27.07 |
| Revenue Next Year | $1.17 | $13.65 |
| P/E Ratio | $13.79 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $24.61 | $2.23 |
| 52 Week High | $37.54 | $6.51 |
| Indicator | GIII | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 41.58 |
| Support Level | $26.77 | $3.24 |
| Resistance Level | $32.39 | $4.23 |
| Average True Range (ATR) | 0.67 | 0.22 |
| MACD | 0.20 | 0.03 |
| Stochastic Oscillator | 26.52 | 25.12 |
G-III Apparel Group Ltd is an apparel manufacturing company. The company makes a wide range of apparel, footwear, and accessories that sells under its own brands, licensed brands, and private-label brands. It has a substantial portfolio for licensed and proprietary brands, anchored by brands: DKNY, Donna Karan, Karl Lagerfeld, Karl Lagerfeld Paris, Vilebrequin, and others. The reportable segments of the company are Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, and sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenue from Wholesale operations.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.